Disease-Modifying Antirheumatic Drugs (DMARDs) are medications used to treat autoimmune conditions like rheumatoid arthritis (RA), psoriatic arthritis, and lupus. Unlike pain relievers, DMARDs target the underlying causes of inflammation and immune system dysregulation, slowing disease progression and preventing joint damage. There are two main types: conventional DMARDs, such as methotrexate and sulfasalazine, and biologic DMARDs, which include TNF inhibitors like adalimumab. DMARDs are often used in combination with other therapies to maximize effectiveness. While highly beneficial, they may have side effects, such as increased infection risk, requiring careful monitoring by healthcare providers for optimal patient safety and outcomes.